Januvia off to good start, data shows

Share this article:
Merck’s new first-in-class diabetes drug Januvia is off to a strong start, according to data from ImpactRx, a market research firm which tracks both new prescriptions and free samples. “In situations where physicians are making a brand choice, it’s clear that Januvia is off to a strong start and Merck looks to be putting the promotional muscle behind it to make that happen,” ImpactRx SVP of strategic development Patrick Angelastro told Reuters. For the week ending Nov. 17, Januvia accounted for 14% of new prescriptions written plus new samples dispensed in the Type 2 diabetes market, according to ImpactRx data. During the same week, Lilly and Takeda’s Actos accounted for 23% of new prescriptions plus samples. Metformin, a generic drug, accounted for 26%. Januvia was running neck and neck with GlaxoSmithKline’s Avandia and Amylin and Lilly’s Byetta among endocrinologists tracked over two weeks ending Nov. 17. Januvia accounted for 20% of new prescriptions plus new samples, compared with 22% for Byetta and 19% for Avandia. Actos lagged behind at 10%, with metformin at 16% among endocrinologists. Januvia won US approval in mid-October to treat adults with Type 2 diabetes and is part of the emerging drug class of DPP-4 inhibitors, which enhance the body's ability to lower elevated blood sugar. Novartis filed for FDA approval of its DPP-4 inhibitor Galvus in March. Earlier this month, the FDA extended its review of Galvus by three months. Analysts say the two drugs have the potential to bring in combined sales of $5 billion by 2010, if no major safety issues emerge.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...